RNA Therapeutics for disease modification of neurological disorders
NEUmiRNA Therapeutics secures €20M in Series A financing
The funding round will accelerate the development of RNA therapies for epilepsy and other neurological disorders
The investment was co-led by new investors, Angelini Ventures and Invivo Partners, with significant participation from Neumirna’s seed investor, Innovestor’s Life Science Fund and other investors. With the new funding, Neumirna is poised to expand its research and development, scale its platform, and drive NMT.001 through the next key stages of development. This funding round marks a pivotal moment for Neumirna as it advances toward its goal of delivering life-changing therapies to patients in need.
“ We are thrilled to have the support of leading international investors, who share our vision of addressing the unmet needs of patients living with neurological disorders. This funding is essential to bring NMT.001 to clinical trials and advance our pipeline.”
—- Prof. Janine Erler, CEO
NEUmiRNA Therapeutics is a Danish pharmaceutical start-up based in Copenhagen.
